abrilumab
mAbexperimental
Abrilumab is a monoclonal antibody designed for the treatment of inflammatory bowel disease, ulcerative colitis, and Crohn's disease. — Wikipedia
Clinical trial activity
5 trials · 3 clinical orgs · 0 marketing orgs
Phase 1
2
Phase 2
3
Phase 3
0
Phase 4
0
Earliest trial started Jul 1, 2010 (NCT01164904)
Timeline
Indications
Mechanism of action
- Integrin alpha-4/beta-7INHIBITOR
Integrin alpha-4/beta-7 inhibitor
Chemistry & pharmacology
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
- Multi-specific
- No
Oral
No
Parenteral
No
Topical
No
Sources
- WikipediaAbrilumab ↗
- ChEMBLCHEMBL3137351 ↗
- ChEMBLCHEMBL2109628 ↗
- ChEMBLCHEMBL2109294 ↗
Also known as
- abrilumab
- amg 181
- amg 181
- amg-181
- medi7183
- medi7183
- medi-7183
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT01959165 | Phase 2 | Nov 21, 2013 | AstraZeneca, Kitasato University |
| NCT01696396 | Phase 2 | Dec 4, 2012 | Amgen |
| NCT01694485 | Phase 2 | Nov 16, 2012 | Amgen |
| NCT01290042 | Phase 1 | Feb 1, 2011 | Amgen |
| NCT01164904 | Phase 1 | Jul 1, 2010 | Amgen |
Showing 5 of 5 trials
Page 1 / 1
Organizations
Research & Development (3)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Amgen | For profit | 4 | 4 | 2 | 2010 |
| AstraZeneca | For profit | 1 | 1 | 1 | 2013 |
| Kitasato University | Academic/Hospital | 1 | 0 | 1 | 2013 |
3 organizations
Page 1 / 1